Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Frances F, Haas"'
Autor:
Fred T. Valentine, Sharon A. Riddler, Frances F. Haas, Donald W. Northfelt, David Henry, John Delehanty, Gary Richmond, Edwin DeJesus, Richard Haubrich, Prakash R. Sista, Ralph DeMasi, William G. Powderly, Melanie A. Thompson, David Wright, Miklos Salgo, Stephen Becker, Margrit Carlson, Peter R. Wolfe, Jacob Lalezari
Publikováno v:
Antiviral Therapy. 8:279-287
Enfuvirtide is a novel antiretroviral that blocks HIV-1 cell fusion and viral entry. This Phase II, controlled, open-label, randomized, multicentre dose-ranging trial explored the safety, antiviral activity and pharmacoki-netics of enfuvirtide, admin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::338666dd967a495a25b118c6624b67c5
https://doi.org/10.1177/135965350300800403
https://doi.org/10.1177/135965350300800403
Autor:
Jacob P, Lalezari, Edwin, DeJesus, Donald W, Northfelt, Gary, Richmond, Peter, Wolfe, Richard, Haubrich, David, Henry, William, Powderly, Stephen, Becker, Melanie, Thompson, Fred, Valentine, David, Wright, Margrit, Carlson, Sharon, Riddler, Frances F, Haas, Ralph, DeMasi, Prokash R, Sista, Miklos, Salgo, John, Delehanty
Publikováno v:
Antiviral therapy. 8(4)
Enfuvirtide is a novel antiretroviral that blocks HIV-1 cell fusion and viral entry. This Phase II, controlled, open-label, randomized, multicentre dose-ranging trial explored the safety, antiviral activity and pharmacokinetics of enfuvirtide, admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e40110131da9aa89683535a2dca90e10
https://pubmed.ncbi.nlm.nih.gov/14518696
https://pubmed.ncbi.nlm.nih.gov/14518696
Autor:
Keith A. Reimann, William G. Powderly, Patrice O. Yarbough, Jeffrey L. Larson, William R. Shanahan, Jeffrey M. Jacobson, Valentin Curt, Frances F. Haas, Edwin DeJesus, Eliot Godofsky, Daniel R. Kuritzkes
Publikováno v:
The Journal of infectious diseases. 189(2)
Background. We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against HIV-1 in vitro, in HIV-infected subjects.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffefa4295286959ba6cae23e4b48dcd8
https://pubmed.ncbi.nlm.nih.gov/14722894
https://pubmed.ncbi.nlm.nih.gov/14722894
Autor:
Kuritzkes DR; Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA. dkuritzkes@partners.org, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V, Shanahan WR Jr
Publikováno v:
The Journal of infectious diseases [J Infect Dis] 2004 Jan 15; Vol. 189 (2), pp. 286-91. Date of Electronic Publication: 2004 Jan 08.